Recent work by our TLC-ART team members revealed that effectiveness and frequency are the two key factors affecting patent and consumer acceptability criteria of long-acting antiretroviral therapy. Even so, effectiveness has the highest significance (p=0.0005).
Michael Carter has highlighted this study in a news article for NAM-AIDSMAP.
The study results are published in AIDS and Behavior in an article titled “A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antitretroviral Therapy Among Persons Living with HIV in the U.S.” by Simoni et al.